Cargando…

Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis

BACKGROUND: Alveolar echinococcosis (AE) is a lethal parasitic disease caused by infection with the metacestode of the dog/fox tapeworm Echinococcus multilocularis, which primarily affects the liver. Although continued efforts have been made to find new drugs against this orphan and neglected diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Yang, Yangyang, Han, Xiumin, Li, Jing, Tian, Mengxiao, Qi, Wenjing, An, Huniu, Wu, Chuanchuan, Zhang, Yao, Han, Shuai, Duan, Liping, Wang, Weisi, Zhang, Wenbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259527/
https://www.ncbi.nlm.nih.gov/pubmed/37312930
http://dx.doi.org/10.2147/IJN.S397526
_version_ 1785057679349121024
author Li, Jun
Yang, Yangyang
Han, Xiumin
Li, Jing
Tian, Mengxiao
Qi, Wenjing
An, Huniu
Wu, Chuanchuan
Zhang, Yao
Han, Shuai
Duan, Liping
Wang, Weisi
Zhang, Wenbao
author_facet Li, Jun
Yang, Yangyang
Han, Xiumin
Li, Jing
Tian, Mengxiao
Qi, Wenjing
An, Huniu
Wu, Chuanchuan
Zhang, Yao
Han, Shuai
Duan, Liping
Wang, Weisi
Zhang, Wenbao
author_sort Li, Jun
collection PubMed
description BACKGROUND: Alveolar echinococcosis (AE) is a lethal parasitic disease caused by infection with the metacestode of the dog/fox tapeworm Echinococcus multilocularis, which primarily affects the liver. Although continued efforts have been made to find new drugs against this orphan and neglected disease, the current treatment options remain limited, with drug delivery considered a likely barrier for successful treatment. METHODS: Nanoparticles (NPs) have gained much attention in the field of drug delivery due to their potential to improve delivery efficiency and targetability. In this study, biocompatible PLGA nanoparticles encapsulating a novel carbazole aminoalcohol anti-AE agent (H1402) were prepared to promote the delivery of the parent drug to liver tissue for treating hepatic AE. RESULTS: H1402-loaded nanoparticles (H1402-NPs) had a uniform spherical shape and a mean particle size of 55 nm. Compound H1402 was efficiently encapsulated into PLGA NPs with a maximal encapsulation efficiency of 82.1% and drug loading content of 8.2%. An in vitro uptake assay demonstrated that H1402-NPs rapidly penetrated the in vitro cultured pre-cyst wall and extensively accumulated in the pre-cysts of E. multilocularis within only 1 h. The biodistribution profile of H1402-NPs determined through ex vivo fluorescence imaging revealed significantly enhanced liver distribution compared to unencapsulated H1402, which translated to improved therapeutic efficacy and reduced systemic toxicity (especially hepatotoxicity and cytotoxicity) in a hepatic AE murine model. Following a 30-day oral regimen (100 mg/kg/day), H1402-NPs significantly reduced the parasitic burden in both the parasite mass (liver and metacestode total weight, 8.8%) and average metacestode size (89.9%) compared to unmedicated infected mice (both p-values < 0.05); the treatment outcome was more effective than those of albendazole- and free H1402-treated individuals. CONCLUSION: Our findings demonstrate the advantages of encapsulating H1402 into PLGA nanoparticles and highlight the potential of H1402-NPs as a promising liver-targeting therapeutic strategy for hepatic AE.
format Online
Article
Text
id pubmed-10259527
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-102595272023-06-13 Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis Li, Jun Yang, Yangyang Han, Xiumin Li, Jing Tian, Mengxiao Qi, Wenjing An, Huniu Wu, Chuanchuan Zhang, Yao Han, Shuai Duan, Liping Wang, Weisi Zhang, Wenbao Int J Nanomedicine Original Research BACKGROUND: Alveolar echinococcosis (AE) is a lethal parasitic disease caused by infection with the metacestode of the dog/fox tapeworm Echinococcus multilocularis, which primarily affects the liver. Although continued efforts have been made to find new drugs against this orphan and neglected disease, the current treatment options remain limited, with drug delivery considered a likely barrier for successful treatment. METHODS: Nanoparticles (NPs) have gained much attention in the field of drug delivery due to their potential to improve delivery efficiency and targetability. In this study, biocompatible PLGA nanoparticles encapsulating a novel carbazole aminoalcohol anti-AE agent (H1402) were prepared to promote the delivery of the parent drug to liver tissue for treating hepatic AE. RESULTS: H1402-loaded nanoparticles (H1402-NPs) had a uniform spherical shape and a mean particle size of 55 nm. Compound H1402 was efficiently encapsulated into PLGA NPs with a maximal encapsulation efficiency of 82.1% and drug loading content of 8.2%. An in vitro uptake assay demonstrated that H1402-NPs rapidly penetrated the in vitro cultured pre-cyst wall and extensively accumulated in the pre-cysts of E. multilocularis within only 1 h. The biodistribution profile of H1402-NPs determined through ex vivo fluorescence imaging revealed significantly enhanced liver distribution compared to unencapsulated H1402, which translated to improved therapeutic efficacy and reduced systemic toxicity (especially hepatotoxicity and cytotoxicity) in a hepatic AE murine model. Following a 30-day oral regimen (100 mg/kg/day), H1402-NPs significantly reduced the parasitic burden in both the parasite mass (liver and metacestode total weight, 8.8%) and average metacestode size (89.9%) compared to unmedicated infected mice (both p-values < 0.05); the treatment outcome was more effective than those of albendazole- and free H1402-treated individuals. CONCLUSION: Our findings demonstrate the advantages of encapsulating H1402 into PLGA nanoparticles and highlight the potential of H1402-NPs as a promising liver-targeting therapeutic strategy for hepatic AE. Dove 2023-06-08 /pmc/articles/PMC10259527/ /pubmed/37312930 http://dx.doi.org/10.2147/IJN.S397526 Text en © 2023 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Jun
Yang, Yangyang
Han, Xiumin
Li, Jing
Tian, Mengxiao
Qi, Wenjing
An, Huniu
Wu, Chuanchuan
Zhang, Yao
Han, Shuai
Duan, Liping
Wang, Weisi
Zhang, Wenbao
Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis
title Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis
title_full Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis
title_fullStr Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis
title_full_unstemmed Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis
title_short Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis
title_sort oral delivery of anti-parasitic agent-loaded plga nanoparticles: enhanced liver targeting and improved therapeutic effect on hepatic alveolar echinococcosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259527/
https://www.ncbi.nlm.nih.gov/pubmed/37312930
http://dx.doi.org/10.2147/IJN.S397526
work_keys_str_mv AT lijun oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT yangyangyang oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT hanxiumin oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT lijing oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT tianmengxiao oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT qiwenjing oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT anhuniu oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT wuchuanchuan oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT zhangyao oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT hanshuai oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT duanliping oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT wangweisi oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis
AT zhangwenbao oraldeliveryofantiparasiticagentloadedplgananoparticlesenhancedlivertargetingandimprovedtherapeuticeffectonhepaticalveolarechinococcosis